RxDoctor Payments Data

Seth Cohen, MD

Urology · New York, NYNPI 1922249135

Payments from drug & device makers

$66,933in general payments, 2019–2025

Across 202 payments — averaging $331.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$58K
  • Endo USA, Inc.$5K
  • Boston Scientific$2K
  • Medtronic$355
  • Coloplast$335
  • Abbott$161
  • plus $809 from 14 others

What the payments were for

  • Consulting fees$21,78033%
  • Speaking & faculty fees$36,15054%
  • Travel & lodging$4,1586%
  • Food & beverage$4,7837%
  • Education$620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Endo Pharmaceuticals Inc.125$57,786
Endo USA, Inc.38$5,021
Boston Scientific4$2,466
Medtronic3$355
Coloplast8$335
Abbott1$161
Antares Pharma, Inc.4$141
Stryker1$140
Procept Biorobotics Corporation1$117
Astellas Pharma US Inc4$100
Urogen Pharma, Inc.2$49
Civco Medical Instruments1$39
ABC Home Medical Supply, Inc.1$36
Hollister Incorporated1$36
Teleflex LLC2$36
Acerus Pharmaceuticals Corporation2$31
Neotract Inc.1$22
Immunitybio, Inc.1$22
Bayer1$21
Merck1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,933 in reported general payments places this provider in the 90th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$242,027
Medicare patients
798
Services billed
8,985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron176$108,457
Tamsulosin Hcl1,589$18,578
Solifenacin Succinate182$8,791
Alfuzosin Hcl ErAlfuzosin Hcl516$8,215
Finasteride620$7,878
Silodosin110$7,323
Oxybutynin Chloride265$2,466
Fesoterodine Fumarate ErFesoterodine Fumarate22$2,192
Dutasteride53$1,914
Tadalafil16$1,674
Terazosin Hcl106$927
Sildenafil Citrate60$894
Doxycycline Hyclate60$769
Oxybutynin Chloride ErOxybutynin Chloride49$726
CefuroximeCefuroxime Axetil59$612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$100$108,457176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 urology providers in New York.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →